A Phase 1/2 interventional study of JNT-517 Suspension and Placebo Suspension in Phenylketonuria, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 15 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies in Phenylketonurias with a site in United States — 16 open to participants now, 21 under way, 4 of them phase 3. Phenylketonurias · United States.
Among the 93 studies in Phenylketonurias with a site in United States, this one is the 9th largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2022, is one of 8 in phase 1/2, and was the 75th registered.
191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.
Browse Phenylketonurias studies →16 of the 93 studies in Phenylketonurias with a site in United States are open now. Recruiting first, the newest first:
Aptatek BioSciences, Inc · Sites in United States
Ages 1+
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–65 · Healthy volunteers
Maze Therapeutics · Sites in United States, France, United Kingdom
Ages 18–75
BioMarin Pharmaceutical · Sites in United States
Ages 18–65
Agios Pharmaceuticals, Inc. · Sites in United States, Poland
Ages 18–69
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 21 · Phase 3 16 · Phase 4 4
First in 1984; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 163 is above the median of 27 across 122 interventional studies indexed under Phenylketonurias.
Median enrollment 33 across the 63 interventional studies, 28 across the 29 observational. Of the 70 that completed or were terminated, 28 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 93 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 6 studies filed under Phenylketonurias — fewer than ten, so there is no comparison to draw.
6 of the studies in Phenylketonurias with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06628128Phase 3Otsuka Pharmaceutical Development & Commercialization, Inc.A Long-Term Study of JNT-517 in Participants With Phenylketonuria | 2027-11-01 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT07713758Otsuka Pharmaceutical Development & Commercialization, Inc.A Trial to Examine if Repinatrabit is Processed Differently in Adults With Reduced Liver or Kidney Function Compared to Adults With Normal Liver and Kidney Function | 2027-02-09 |
| NCT07220265University of Missouri-ColumbiaImpact of Phenylalanine Elevations on Brain and Cognition in Adult PKU Carriers | 2027-03-01 |
| NCT07551921Aptatek BioSciences, IncPheCheck™ Validation Study | 2027-03-20 |
Add all 6 to your calendar (.ics) → With an account.
Among the 93 studies in Phenylketonurias with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of Parts A and B of this Phase 1/2, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of single (SAD) and multiple (MAD) ascending doses of oral JNT-517 in healthy participants. In Part C, the goal is to evaluate the differences in bioavailability between a tablet and suspension formulation of JNT-517 and the food effect in healthy volunteers. All participants in Part C will receive JNT-517. The goal of Part D is to assess the safety, tolerability, PK, and effect on urinary Phe and other amino acids of JNT-517 in participants with phenylketonuria (PKU). Participants in Part D will receive either JNT-517 or placebo and will be blinded to their treatment assignment.
The study consists of 6 parts:
In each part, participants will complete a Screening Period, a Treatment Period, and a Follow-up Period for safety.
Key Inclusion Criteria:
Parts A, B, C, and F:
Non-smoker for at least 2 weeks prior to dosing and willing to abstain during the study.
Part D and E:
BMI of 18-40 kg/m2.
All Parts:
Key Exclusion Criteria:
All Parts:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of JNT-517 or placebo in fasted state.
Drug: JNT-517 Suspension · Drug: Placebo Suspension
JNT-517 or placebo once or twice daily for 14 days, with first daily dose given after an overnight fast.
Drug: JNT-517 Suspension · Drug: Placebo Suspension
Single dose of JNT-517 suspension, JNT-517 tablet in a fasted state, and JNT-517 tablet in a fed state in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.
Drug: JNT-517 Suspension · Drug: JNT-517 Tablet
Single dose of JNT-517 tablet in a fasted state, JNT-517 tablet in a fed state, and JNT-517 suspension in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.
Drug: JNT-517 Suspension · Drug: JNT-517 Tablet
Single dose of JNT-517 tablet in a fed state, JNT-517 suspension, and JNT-517 tablet in a fasted state in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.
Drug: JNT-517 Suspension · Drug: JNT-517 Tablet
JNT-517 or placebo daily for 4 weeks. Dose is based on data from Parts A, B, and C.
Drug: JNT-517 Tablet · Drug: Placebo Tablet
JNT-517 in on-site compounded suspension
On-site compounded placebo suspension
JNT-517 tablets, 25 mg and 75 mg
Matching film-coated placebo tablet
Number of participants with treatment-emergent adverse events
Reported based on results of 12-lead ECGs, vital signs, clinical laboratory tests, and other medical assessments.
Time frame: Parts A/C/F: Screening to Day 8; Part B: Screening to Day 21; Part D/E: Screening to Day 35
Plasma area under the concentration-time curve (AUC) of JNT-517
Time frame: Parts A/C/F: pre-dose to 72 hrs post-dose on Day 1; Part B: pre-dose to 24 hrs post-dose on Days 1, 14 and pre-dose on Days 3, 13; Part D/E: pre-dose to 4 hrs post-dose on Days 1, 14, 28
Maximum observed plasma concentration (Cmax) of JNT-517
Time frame: Parts A/C/F: pre-dose to 72 hrs post-dose on Day 1; Part B: pre-dose to 24 hrs post-dose on Days 1, 14 and pre-dose on Days 3, 13; Part D/E: pre-dose to 4 hrs post-dose on Days 1, 14, 28
Time to maximum plasma concentration (Tmax) of JNT-517
Time frame: Parts A/C/F: pre-dose to 72 hrs post-dose on Day 1; Part B: pre-dose to 24 hrs post-dose on Days 1, 14 and pre-dose on Days 3, 13; Part D/E: pre-dose to 4 hrs post-dose on Days 1, 14, 28
Plasma terminal half-life (t1/2) of JNT-517
Time frame: Parts A/C/F: pre-dose to 72 hrs post-dose on Day 1; Part B: pre-dose to 24 hrs post-dose on Days 1, 14 and pre-dose on Days 3, 13; Part D/E: pre-dose to 4 hrs post-dose on Days 1, 14, 28
Comparison of Tmax of JNT-517 in fed and fasted states
Part C only
Time frame: Pre-dose to 72 hrs post-dose on Day 1
Comparison of Cmax of JNT-517 in fed and fasted states
Part C only
Time frame: Pre-dose to 72 hrs post-dose on Day 1
Comparison of AUC of JNT-517 in fed and fasted states
Part C only
Time frame: Pre-dose to 72 hrs post-dose on Day 1
Changes in urinary amino acid levels
Part D/E only. Urine samples will be collected at the indicated timepoints and analyzed for amino acid levels, including Phe.
Time frame: Screening and Days 1, 7, 14, 21, 28
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
No publications or documents are linked to this record.
Ran from Oct 2022 to primary completion in Jul 2025, 32 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Repinatrabit
Otsuka Pharmaceutical Development & Commercialization, Inc. →